Quarterly report pursuant to Section 13 or 15(d)

Revenue and Accounts Receivable - Additional Information (Detail)

v3.4.0.3
Revenue and Accounts Receivable - Additional Information (Detail)
$ in Thousands
3 Months Ended
Mar. 31, 2016
USD ($)
company
Mar. 31, 2015
USD ($)
company
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Revenue $ 6,068 $ 4,370
Number of companies that accounted for approximately 10% or more of revenue | company 2 2
Payor | Testing Volume | Clinical Testing    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Percentage of benchmark 35.00% 72.00%
Payor | Testing Volume | Community Hospitals    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Percentage of benchmark 8.00% 24.00%
Payor | Sales | Customer One | 10% or More Clinical Revenue    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Percentage of benchmark 11.00% 29.00%
Payor | Sales | Customer Two | 10% or More Clinical Revenue    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Percentage of benchmark 10.00% 22.00%
Biopharma Services    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Revenue $ 3,350 $ 3,331
Biopharma Services | Response Genetics, Inc.    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Revenue 459  
Clinical Services    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Revenue 2,456 $ 873
Clinical Services | Response Genetics, Inc.    
Accounts, Notes, Loans and Financing Receivable [Line Items]    
Revenue $ 1,704